Dupilumab for treating moderate to severe prurigo nodularis (TA955)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 December 2023
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)Product type:GuidanceProgramme:NICE guidelinePublished: 2 March 2021
Impetigo: antimicrobial prescribing (NG153)Product type:GuidanceProgramme:NICE guidelinePublished: 26 February 2020
Cellulitis and erysipelas: antimicrobial prescribing (NG141)Product type:GuidanceProgramme:NICE guidelinePublished: 27 September 2019
Endoscopic ablation for a pilonidal sinus (IPG646)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 17 April 2019
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)Product type:AdviceProgramme:Evidence summaryPublished: 11 May 2022
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)Product type:AdviceProgramme:Evidence summaryPublished: 5 January 2021
InterDry for intertrigo (MIB192)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 September 2019
Nemolizumab for treating prurigo nodularis [ID6451]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2025
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rezafungin for untreated invasive candidiasis TS ID 10768Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating bullous pemphigoid [ID6479]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC